Jefferies Starts Antares Pharma (ATRS) at Buy; Sees Over 100% Upside

Jefferies initiates coverage on Antares Pharma (NASDAQ: ATRS) with a Buy rating and a price target of $5.00.

Analyst Anthony Petrone commented, "ATRS is at a growth inflection following the recent OTREXUP settlement and ahead of the VIBEX EpiPEN launch with Teva. Risk-reward favorable considering OTREXUP/EpiPEN cycles, pipeline potential, and discounted valuation."

For an analyst ratings summary and ratings history on Antares Pharma click here. For more ratings news on Antares Pharma click here.

Shares of Antares Pharma closed at $2.15 yesterday.

You May Also Be Interested In

• UBS Upgrades UDR, Inc. (UDR) to Buy
• HSBC Upgrades UPS (UPS) to Buy, 'Back to earnings growth'
• Mr. Cooper Group Inc. (COOP) PT Raised to $90 at Deutsche Bank